Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 3/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 3/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6319930 | 0.87 | CDK1 (0.37) | CDK1MAPKAPK2MEN1KMT2APIM1 | |
| SCHEMBL6315169 | 0.85 | MAPKAPK2 (0.56) | CDK1MAPKAPK2MAPTPRKD1 | |
| SCHEMBL6311758 | 0.84 | MAPKAPK2 (0.44) | CDK1MAPKAPK2MEN1KMT2AMAPT | |
| SCHEMBL6311862 | 0.83 | MAPT (0.40) | CDK1MAPKAPK2MEN1KMT2AMAPT | |
| SCHEMBL6311332 | 0.82 | MAPT (0.47) | MEN1KMT2APIM1PIM2MAPT | |
| SCHEMBL6313843 | 0.82 | PIM1 (0.36) | CDK1MAPKAPK2PIM1PIM2MAPT | |
| SCHEMBL6320041 | 0.82 | PRKD1 (0.36) | CDK1MAPKAPK2PIM1PIM2MAPT | |
| SCHEMBL6320340 | 0.82 | PIM1 (0.37) | CDK1MAPKAPK2PIM1PIM2MAPT | |
| SCHEMBL6312999 | 0.80 | MAPT (0.57) | MEN1KMT2APIM1PIM2MAPT | |
| SCHEMBL6314267 | 0.78 | MAPKAPK2 (0.58) | CDK1MAPKAPK2MAPTPRKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250765-A1 | Diazepinones as antiviral agents | CHO HIDETSURA | 2005-11-10 | — | — | US | claimed |
| US-20040116410-A1 | Diazepinones as antiviral agents | CHO HIDETSURA (JP) | 2004-06-17 | — | — | US | claimed |
| WO-2002014324-A2 | DIAZEPINONES AS ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2002-02-21 | — | — | WO | claimed |
| US-20050250765-A1 | Diazepinones as antiviral agents | CHO HIDETSURA | 2005-11-10 | — | — | US | disclosed |
| US-20040116410-A1 | Diazepinones as antiviral agents | CHO HIDETSURA (JP) | 2004-06-17 | — | — | US | disclosed |
| WO-2002014324-A2 | DIAZEPINONES AS ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250765-A1 | Diazepinones as antiviral agents | ZC3HAV1, ECI1, ZC3HAV1L | CDK1 274/4885MAPKAPK2 3952/4885MEN1 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.